SCHEMBL5317320

SCHEMBL5317320

CC(C)(C)OC(=O)N1CCc2c(c(C(=O)NC3C4(C)CCC(C4)C3(C)C)nn2-c2ccccc2)C1

nearest known ligand 0.46

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 10/20 0.46
CNR1 P21554 6/20 0.45
MAP3K14 Q99558 1/20 0.43
POLB P06746 1/20 0.42
TAS1R3 Q7RTX0 1/20 0.41
TAS1R1 Q7RTX1 1/20 0.41
DDB1 Q16531 1/20 0.40
CRBN Q96SW2 1/20 0.40
LMNA P02545 2/20 0.39
THRB P10828 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5313689 0.92 CNR2 (0.48) CNR2CNR1TAS1R3TAS1R1
SCHEMBL5314762 0.90 CNR2 (0.48) CNR2CNR1TAS1R3TAS1R1
SCHEMBL5313239 0.88 CNR2 (0.44) CNR2CNR1TAS1R3TAS1R1DDB1
SCHEMBL5317196 0.88 CNR2 (0.45) CNR2CNR1TAS1R3TAS1R1
SCHEMBL5317316 0.83 CNR2 (0.41) CNR2CNR1TAS1R3TAS1R1DDB1
SCHEMBL14003103 0.82 CNR2 (0.49) CNR2CNR1TAS1R3TAS1R1
SCHEMBL13871306 0.81 CNR2 (0.56) CNR2CNR1TAS1R3TAS1R1
SCHEMBL5314686 0.80 CNR2 (0.48) CNR2CNR1TAS1R3TAS1R1
SCHEMBL1174133 0.79 CNR2 (0.42) CNR2CNR1TAS1R3TAS1R1
SCHEMBL5317181 0.79 CNR2 (0.45) CNR2CNR1TAS1R3TAS1R1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1804791-A1 TETRAHYDRO PYRIDINYL PYRAZOLE CANNABINOID MODULATORS JANSSEN PHARMACEUTICA N.V. (BE) 2007-07-11 EP claimed
WO-2006049880-A1 TETRAHYDRO PYRIDINYL PYRAZOLE CANNABINOID MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2006-05-11 WO claimed
US-20060089378-A1 Tetrahydro-pyridinyl pyrazole cannabinoid modulators JANSSEN PHARMACEUTICA, N.V. (BE) 2006-04-27 US claimed
EP-1804791-A1 TETRAHYDRO PYRIDINYL PYRAZOLE CANNABINOID MODULATORS JANSSEN PHARMACEUTICA N.V. (BE) 2007-07-11 EP disclosed
WO-2006049880-A1 TETRAHYDRO PYRIDINYL PYRAZOLE CANNABINOID MODULATORS JANSSEN PHARMACEUTICA, N.V. (BE) 2006-05-11 WO disclosed
US-20060089378-A1 Tetrahydro-pyridinyl pyrazole cannabinoid modulators JANSSEN PHARMACEUTICA, N.V. (BE) 2006-04-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060089378-A1 Tetrahydro-pyridinyl pyrazole cannabinoid modulators CNR2, CNR1, GPR18 CNR2 1/4885CNR1 2/4885MAP3K14 1517/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.